Initial results of ixekizumab efficacy and safety in real‐world plaque psoriasis patients: a multicentre retrospective study

Background Ixekizumab (anti‐IL17A) is effective as treatment for moderate‐to‐severe plaque psoriasis, but real‐life data on effectiveness and safety are currently very limited. Objective To evaluate the efficacy and safety of ixekizumab in a cohort of real‐life plaque psoriasis patients. Methods Ret...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of the European Academy of Dermatology and Venereology 2019-03, Vol.33 (3), p.553-559
Hauptverfasser:	Deza, G., Notario, J., Lopez‐Ferrer, A., Vilarrasa, E., Ferran, M., del Alcazar, E., Carrascosa, J.M., Corral, M., Salleras, M., Ribera, M., Puig, L., Pujol, R. M., Vidal, D., Gallardo, F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Biological Products - therapeutic use Dermatologic Agents - adverse effects Dermatologic Agents - therapeutic use Female Humans Injection Site Reaction - etiology Male Middle Aged Psoriasis - drug therapy Retreatment Retrospective Studies Severity of Illness Index
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!